Development of Evaluation Method for Drug Release Propreties in Drug Eluting Stent |
Song, J.M.
(Medical Device Team, Medical Device Assessment Headquarter, Korea Testing & Research institute)
Baek, H. (Medical Device Team, Medical Device Assessment Headquarter, Korea Testing & Research institute) Lee, S.Y. (Medical Device Team, Medical Device Assessment Headquarter, Korea Testing & Research institute) Jang, D.H. (Medical Device Team, Medical Device Assessment Headquarter, Korea Testing & Research institute) Seo, M.Y. (Medical Device Team, Medical Device Assessment Headquarter, Korea Testing & Research institute) Park, G.J. (Medical Device Team, Medical Device Assessment Headquarter, Korea Testing & Research institute) Maeng, Eun-Ho (Medical Device Team, Medical Device Assessment Headquarter, Korea Testing & Research institute) |
1 | 한국보건산업진흥원, 스텐트 시장동향, 2005. |
2 | P. A. Lemos, P. W. Serruys, R. T. Domburg, F. Saia, C. A. Arampatzis, A. Hoye, M. Degertekin, K. Tanabe, J. Daemen, T. K. K. Liu, E. McFadden, G. Sianos, S. H. Hofma, P. C. Smits, W. J. Giessen and P. J. Feyter, "Unrestricted Utilization of Sirolimus-Eluting Stents Compared With Conventional Bare Stent Implantation in the Real World," Circulation, vol. 109, pp. 190-195, 2004. DOI ScienceOn |
3 | S. J. Park, "Drug-Eluting Stent : Present and Future," J. Korean Med. Assoc. vol. 51, no. 4, pp. 299-305, 2008. DOI ScienceOn |
4 | A. Seidlitz, S. Nagel, B. Semmling, K. Sternberg, H. K. Kroemer, W. Weitschies, "In vitro Dissolution Testing of Drug- Eluting Stents," Current Pharmaceutical Biotechnology, vol. 14, pp. 67-75, 2013. |
5 | R. S. Schwartz, E. R. Edelman, A. Carter, N. Chronos, C. Regoers, K. A. Robinson, R. Waksman, J. Weinberger, R. L. Wilensky, D. N. Jenson, B. D. Zuckerman, E. Virmani, "Drug-Eluting Stents in Preclinical Studies: Recommendation Evaluation from a Consensus Group," Circulation, vol. 106, pp. 1867-1873, 2002. DOI ScienceOn |
6 | W. Khan, S. Farah, A. Nyska, A. J. Domb, "Carrier Free Rapamycin Loaded Drug Eluting Stent: In Vitro and In vivo Evaluation," J Control Release, vol. 168, no. 1, pp. 70-76, 2013. DOI ScienceOn |
7 | C. P. Naseerali, P. R. Hari, K. Sreenivasan, "The Release Kinetics of Drug Eluting Stents Containing Sirolimus as Coated Drug: Role of Release Media," J Chromatogr B Analyt Biomed Life Sci, vol. 878, pp. 709-712, 2010. DOI ScienceOn |
8 | S. Farah, W. Kahn, A. J. Domb, "Crystalline Coating of Rapamycin onto a Stent: Process Development and Characterization," Int J Pharm, vol. 10, 99.20-28, 2013. |
9 | K. Steigerwald, S. Merl, A. Kastrati, A. Wienczorek, M. Vorpahl, R. Mannhold, M. Vogeser, J. Hausleiter, M. Joner, A. Schomig, R. Wessely, "The Pre-clinical Assessment of Rapamycin-Eluting, Durable Polymer-Free Stent Coating Concepts," Biomaterials, pp. 1-6, 2008. |
10 | R. S. Schwartz, E. Edelman, R. Virmani, A. Carter, J. F. Granada, G. L. Kaluza, N. A. F. Chronos, K. A. Robinson, R. Waksman, J. Weinberger, G. J. Wilson, R. L. Wilensky, "Drug- Eluting Stents in Preclinical Studies: Updated Concensus Recommendations for Preclinical Evaluation," Circ Cardiovasc Intervent, pp. 141-153, 2008. |
11 | M. Merciadez, L. Alquier, R. Mehta, A. Patel, A. Wang, "A Novel Method for the Elution of Sirolimus (Rapamycin) in Drug-Eluting Stents," Dissolution Technolodies, vol. 18, pp. 37-42, 2011. DOI |
12 | F. C. Nelson, S. J. Stachel, C. P. Eng, S. N. Seghal, "Manipulation of the C(22)-C(27) Region of Rapamycin: Stability Issues and Biological Implications," Bioorg Med Chem Lett, vol. 9, pp. 295-300, 1999. DOI ScienceOn |